Denali Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$15.5M Buy
12,917
+3,625
+39% +$3.7M 1.56% 6
2026
Q1
$8.55M Buy
9,292
+2,571
+38% +$2.61M 0.95% 13
2025
Q4
$7.22M Sell
6,721
-51
-0.8% -$48.8K 0.8% 33
2025
Q3
$5.17M Sell
6,772
-6,004
-47% -$4.47M 0.58% 61
2025
Q2
$9.96M Sell
12,776
-740
-5% -$575K 1.04% 13
2025
Q1
$11.2M Sell
13,516
-172
-1% -$143K 1.27% 9
2024
Q4
$10.6M Sell
13,688
-1,865
-12% -$1.54M 1.11% 11
2024
Q3
$13.8M Buy
+15,553
New +$14M 1.48% 7

Other funds holding LLY

Denali Advisors's LLY Position: Q2 2026 in Review

Denali Advisors increased its Eli Lilly (LLY) stake by 39% in Q2 2026, buying an estimated $3.7M and bringing the position to 12,917 shares worth $15.5M. The position accounts for 1.56% of the portfolio, ranked #6.

Denali Advisors first reported a position in LLY in Q3 2024 and has held it in 8 quarters since. 4,602 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Denali Advisors held 12,917 shares of Eli Lilly worth $15.5M as of Q2 2026.
  • Denali Advisors bought 3,625 Eli Lilly shares in Q2 2026, an estimated $3.7M.
  • Eli Lilly made up 1.56% of Denali Advisors's portfolio in Q2 2026, its #6 holding.
  • Denali Advisors first reported a position in Eli Lilly in Q3 2024 and has held it in 8 quarters since.
  • 4,602 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Denali Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.